Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021
Relmada Therapeutics (Nasdaq: RLMD) announced the presentation of data on its lead product candidate, REL-1017, at the ASPET Annual Meeting, which runs virtually from April 27 to April 30, 2021. The poster titled, REL-1017 (esmethadone) Did Not Produce Initial or Cumulative Neurotoxic Effects, highlights REL-1017's safety profile and its potential as a rapid-acting antidepressant. Previously, REL-1017 received FDA Fast Track designation for treating major depressive disorder (MDD) as an adjunctive treatment following positive Phase 2 trial results.
- REL-1017 demonstrated statistically significant antidepressant effects compared to placebo in Phase 2 trials.
- FDA granted Fast Track designation for REL-1017 as an adjunctive treatment for MDD.
- None.
NEW YORK, April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in a poster at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and April 30, 2021.
Details of the presentation are below:
Poster Number: R2195
Title: REL-1017 (esmethadone) Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons
The abstract is available on the meeting website and the poster is also available online to registered attendees from April 13 to May 31, 2021.
About REL-1017
REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults. Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-poster-presentation-at-the-american-society-for-pharmacology-and-experimental-therapeutics-annual-meeting-at-experimental-biology-2021-301277762.html
SOURCE Relmada Therapeutics, Inc.
FAQ
What is the significance of the REL-1017 presentation at ASPET Annual Meeting?
When is the ASPET Annual Meeting taking place?
What are the results of the Phase 2 trial for REL-1017?
What does FDA Fast Track designation mean for REL-1017?
What is the focus of Relmada Therapeutics?
